scholarly journals Meta-analysis links dietary branched-chain amino acids to metabolic health in rodents

BMC Biology ◽  
2022 ◽  
Vol 20 (1) ◽  
Author(s):  
Samantha M. Solon-Biet ◽  
Lucy Griffiths ◽  
Sophie Fosh ◽  
David G. Le Couteur ◽  
Stephen J. Simpson ◽  
...  

Abstract Background The role of dietary branched chain amino acids (BCAAs) and their effect on metabolic health is complex. How dietary BCAA levels and their interaction with background nutrition affect health is unclear. Here, we used meta-analysis and meta-regression, together with the nutritional modelling, to analyse the results of rodent studies that increased the level of dietary BCAAs and measured circulating levels, outcomes related to metabolic health, body mass and food intake. Results Across all studies, increasing dietary BCAAs resulted in increased levels of circulating BCAAs. These effects, however, were heavily moderated by background dietary levels whereby on high BCAA diets, further increases were not reflected in the blood. Impaired glucose tolerance was associated with elevated dietary BCAAs, with the greatest effect occurring with a simultaneous increase in total protein intake. Effects of dietary BCAAs on plasma glucose, insulin, or HOMA emerged only when dietary macronutrient background was considered. We found that elevated dietary BCAAs increases % body fat, with largest increases in adiposity occurring when BCAAs are increased on a high protein, low carbohydrate dietary background. Finally, we found that increased dietary BCAAs were associated with increased food intake when the background diet was low in BCAAs. Conclusion Our data highlights the interaction between BCAAs and background nutrition. We show that the effects of BCAAs on metabolic health cannot be studied in isolation but must be considered as part of complex mixture of dietary components.

2017 ◽  
Vol 596 (4) ◽  
pp. 623-645 ◽  
Author(s):  
Nicole E. Cummings ◽  
Elizabeth M. Williams ◽  
Ildiko Kasza ◽  
Elizabeth N. Konon ◽  
Michael D. Schaid ◽  
...  

2018 ◽  
Vol 56 (2) ◽  
pp. 187-195 ◽  
Author(s):  
Akinkunmi Paul Okekunle ◽  
Meng Zhang ◽  
Zhen Wang ◽  
Justina Ucheojor Onwuka ◽  
Xiaoyan Wu ◽  
...  

2020 ◽  
Vol 98 (Supplement_3) ◽  
pp. 16-16
Author(s):  
Mike D Tokach ◽  
Henrique S Cemin ◽  
Hayden R Kerkaert ◽  
Jason C Woodworth ◽  
Steve S Dritz ◽  
...  

Abstract Excess dietary leucine stimulates the key enzymes involved in branched-chain catabolism causing breakdown of all branched-chain amino acids, including isoleucine and valine. Branched-chain amino acids share a common brain transporter with other large neutral amino acids (LNAA). Excess levels of one of the LNAA increases brain uptake of that amino acid and decreases the uptake of the other LNAA, including tryptophan. Thus, excess leucine can impact the requirements for many amino acids. From a practical basis, this effect was first demonstrated with diets containing blood meal, but was thought to be of limited concern unless high blood meal diets were fed. Use of corn dried distillers grains with solubles (DDGS) or high protein DDGS in corn-based diets results in diets containing excess leucine. These high leucine levels are of limited concern if adequate levels of other branched-chain amino acids and LNAA are fed, which is often the case if the diet consists largely of intact protein sources. Feed grade amino acids, such as L-lysine, L-threonine, L-tryptophan, DL-methionine, L-valine, and L-isoleucine have been widely adopted as a means to lower nitrogen excretion and diet cost. Including these amino acids in diets containing corn products reduces dietary leucine; but the resulting diets are formulated near the requirement for the first 6 limiting amino acids, including valine, isoleucine, and tryptophan, while still being high in leucine. The excess leucine increases the requirements for valine, isoleucine, and possibly other LNAA, such as tryptophan and possibly others. The exact relationship between these amino acids and how to handle them in practical diet formulation is still being elucidated; however, recent meta-analysis and experimental data confirm the importance of these ratios and provide useful direction for future research.


Nutrients ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 3029
Author(s):  
Mariwan H. Sayda ◽  
Bethan E. Phillips ◽  
John P. Williams ◽  
Paul L. Greenhaff ◽  
Daniel J. Wilkinson ◽  
...  

Leucine, isoleucine and valine (i.e., the branched chain amino acids, BCAA) play a key role in the support of tissue protein regulation and can be mobilized as energy substrates during times of starvation. However, positive relationships exist between elevated levels of BCAA and insulin resistance (IR). Thus, we sought to investigate the links between fasting plasma BCAA following a progressive resistance exercise training (RET) programme, an intervention known to improve metabolic health. Fasting plasma BCAA were quantified in adults (young: 18–28 y, n = 8; middle-aged: 45–55 y, n = 9; older: 65–75 y, n = 15; BMI: 23–28 kg/m2, both males and females (~50:50), in a cross-sectional, intervention study. Participants underwent 20-weeks whole-body RET. Measurements of body composition, muscle strength (1-RM) and metabolic health biomarkers (e.g., HOMA-IR) were made at baseline and post-RET. BCAA concentrations were determined by gas-chromatography mass spectrometry (GC-MS). No associations were observed across age with BCAA; however, RET elicited (p < 0.05) increases in plasma BCAA (all age-groups), while HOMA-IR scores reduced (p < 0.05) following RET. After RET, positive correlations in lean body mass (p = 0.007) and strength gains (p = 0.001) with fasting BCAA levels were observed. Elevated BCAA are not a robust marker of ageing nor IR in those with a healthy BMI; rather, despite decreasing IR, RET was associated with increased BCAA.


2016 ◽  
Vol 64 (4) ◽  
pp. 926.1-926
Author(s):  
DW Lamming ◽  
NE Cummings ◽  
S Arriola Apelo ◽  
JC Neuman ◽  
B Schmidt ◽  
...  

“You are what you eat,” is a well-known axiom coined over 100 years ago by the French politician and epicure Jean Anthelme Brillat-Savarin. With this in mind, it is unsurprising that as diets across the United States and around the globe have become increasingly unhealthy, we have become unhealthy as well. Linked closely with the obesity epidemic, diabetes now affects over 29 million Americans (12.3% of adults over the age of 20). An additional 86 million Americans over the age of 20 are estimated to have pre-diabetes, making this disease an urgent health care problem.As type 2 diabetes is so closely associated with diet and obesity, it is possible that dietary interventions might prove more effective and affordable than pharmaceutical options. Reduced-calorie diets are notoriously difficult to sustain, but altering the macronutrient composition of the diet while keeping the total number of calories constant is an intriguing alternative. Recent findings suggest that a low protein, high carbohydrate diet can increase lifespan and improve metabolic health in rodents, yet the applicability of these studies to humans as well as the mechanisms driving this effect remain unclear.Here, we demonstrate for the first time in a randomized controlled trial that placing humans on a moderately protein restricted (PR) diet for one month improves multiple markers of metabolic health in humans, including fasting blood glucose and body mass index. We observed similar beneficial effects of moderate PR on the metabolic health of mice over the course of 3 months, with improved glucose tolerance starting as early as three weeks after initiation of the diet. While the precise dietary components altered in a PR diet that promote metabolic health have never been defined, we hypothesized that decreased levels of specific amino acids – the building blocks of protein – might mediate these effects.Several studies have shown that insulin-resistant humans have increased serum levels of the three branched-chain amino acids (BCAAs) – leucine, isoleucine, and valine. To study the contribution of reduced BCAAs to the beneficial effects of a PR diet, we placed mice on one of four amino acid (AA) defined diets: Control (21% of calories from AAs), Low AA (7% of calories from AAs), a Low BCAA diet in which the level of the three BCAAs was the same as in the Low AA (7%) diet, but all other AAs were at the level of a Control (21%) diet; and a Low Leucine diet in which only the level of leucine was reduced by 2/3rds. The caloric density of the diet as well as dietary fat was kept constant. We tracked weight and body composition over the course of three months, periodically testing glycemic control through the use of glucose, insulin, and pyruvate tolerance tests and the analysis of circulating hormones. At the end of the experiment, we isolated islets for the ex vivo analysis of glucose stimulated insulin secretion, and collected tissues and blood for subsequent phosphoproteomic and genomic analysis.We find that a specific reduction in dietary branched chain amino acids (BCAAs) is sufficient to improve glucose tolerance and body composition equivalently to a PR diet in mice. Intriguingly, the improved metabolic health of mice fed a low BCAA diet is independent of increased FGF21, an insulin sensitizing hormone believed to be responsible for many of the positive metabolic effects of a PR diet. Switching mice induced to be obese and insulin resistant through high-fat diet feeding to a diet with reduced levels of BCAAs stimulates rapid improvements in glucose tolerance and fat mass loss. Our results highlight a critical role for dietary quality in glycemic control, and suggest that a reduction of dietary BCAAs, or pharmacological interventions in this pathway, may offer a novel and translatable therapy to promote metabolic health.


2018 ◽  
Vol 596 (13) ◽  
pp. 2469-2470
Author(s):  
Jacob G. Anderson ◽  
Kenzie Hintze ◽  
Erik D. Marchant

2021 ◽  
Vol 20 ◽  
pp. 153473542199755
Author(s):  
Elise Cogo ◽  
Mohamed Elsayed ◽  
Vivian Liang ◽  
Kieran Cooley ◽  
Christilynn Guerin ◽  
...  

Background: Branched-chain amino acids (BCAAs; leucine, isoleucine, and valine) are essential amino acids involved in immune responses, and may have roles in protein malnutrition and sarcopenia. Furthermore, certain liver diseases have been associated with a decreased Fischer’s ratio (BCAAs to aromatic amino acids; phenylalanine, tyrosine, and tryptophan). We aimed to evaluate the safety and efficacy of BCAAs use in patients with cancer undergoing surgery. Methods: MEDLINE, Embase, and CENTRAL were searched (inception to July 24, 2020) for randomized controlled trials (RCTs) and comparative observational studies in English evaluating BCAAs (alone or in combinations) during the oncological peri-operative period. Study selection, data extraction, and quality appraisal were done in duplicate. RCT risk-of-bias was appraised using Cochrane Risk-of-Bias tool, and observational studies’ quality assessment was conducted with Newcastle-Ottawa Scale. Meta-analyses were conducted when appropriate. Results: 20 articles were included comprising 13 RCTs and 6 observational cohort studies in 7 reports and 2019 total participants overall. Among 13 RCTs, 77% involved liver cancer. Methodological study quality scored substantial risk-of-bias across most RCTs. Meta-analysis of RCTs found a 38% decreased risk of post-operative infections in BCAAs group compared to controls (RR = 0.62; 95% CI = 0.44 to 0.87; P = .006; number of RCTs, k = 6; total sample size, N = 389; I2 = 0%). BCAAs were also found to be beneficial for ascites (RR = 0.55; 95% CI = 0.35 to 0.86; P = .008; k = 4; N = 296; I2 = 0%), body weight (MD = 3.24 kg; 95% CI = 0.44 to 6.04; P = .02; k = 3; N = 196; I2 = 24%), and hospitalization length (MD = −2.07 days; 95% CI = −3.97 to −0.17; P = .03; k = 5; N = 362; I2 = 59%). No differences were found between BCAAs and controls for mortality, recurrence, other post-operative complications (liver failure, edema, pleural effusion), blood loss, quality of life, ammonia level, and prothrombin time. No serious adverse events were related to BCAAs; however, serious adverse events were reported due to intravenous catheters. No safety concerns from observational studies were identified. Conclusions: Branched-chain amino acids during the oncological surgical period demonstrated promise in reducing important post-operative morbidity from infections and ascites compared to controls. Blinded, placebo-controlled confirmatory trials of higher methodological quality are warranted, especially using oral, short-term BCAAs-enriched supplements within the context of recent ERAS programs. PROSPERO registration: CRD42018086168.


Sign in / Sign up

Export Citation Format

Share Document